Stock

Illumina

ILMN
64
Medical - Diagnostics & Research · Healthcare
Also trades as: 0J8Z.L GBP 1.98 (-1.01%)
Price
$198.00
-9.01 (-4.35%)
pre-market:$195.00-1.52%
Market Cap
$29.94B
Exchange
NASDAQ
Cost to borrow
5.5%
notable short interest
2-year average 4.5%
Winston Score
64
Winston is curious
A decent business — some strong pillars, some weaker.
Data as of Nov 17, 2026 · filings through Sep 27, 2026

§How the score breaks down

Quality
Strong
25/30
↳ Moat
Wide moat
gross margin 73.5%
Growth
Strong
14/20
Cash Flow
Exceptional
10/10
Stability
Strong
8/10
Valuation
Weak
2/10
Ownership
Weak
2/15
Dividends
Not counted
n/a

61 of 95 counted points = Winston Score 64. Pillars marked n/a do not apply to this company and are left out of the total.

Share count rising — dilution

+3.3% over 3y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 151.0M (2022) → 156.0M (2025)

§Winston Score History

The full picture

Illumina makes machines and chemicals that read DNA — a process called genetic sequencing. Its main products are sequencing instruments and the consumable reagents (chemical kits) that labs must buy repeatedly to run tests. Customers include hospitals, university research labs, pharmaceutical companies, and government health agencies around the world. Illumina is the dominant global leader in DNA sequencing equipment, controlling the large majority of the market.

The company earns money two ways: selling the sequencing machines upfront and then selling the consumables and software that customers need to keep using them. This "razor and blades" model creates steady, recurring revenue. Illumina operates globally, with significant sales in the US, Europe, and Asia, and generated roughly $4 billion in annual revenue in recent fiscal periods. Its deep installed base of instruments and proprietary chemistry create a strong competitive moat, but the key risk is growing competition from newer sequencing technologies, particularly from companies like Pacific Biosciences and Oxford Nanopore.

Politician Trades

5 trades / 12mo

3 Congressional buys and 2 sells on ILMN in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+4.2% YoY

YoY Growth Rate

Slow revenue growth

Reported EPS Growth

+49.0% YoY

Quarterly reporting periods ended:

28 Sept 2025: $0.98

27 Sept 2026: $1.46

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS increased year over year

R&D Spend

$967M/ year

↓ Declining (-17% vs prior year)

22.3% of revenue

In line with sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.3%ownership

↓ Declining

Insider ownership declining — could be dilution or selling

Cash Position

Cash flow positive

$1.3B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Illumina is growing revenue at 4% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
73.5%
Premium pricing power — 73.5% gross margin
Profit after running costs
Operating Margin
27.0%
Excellent — 27.0% operating margin
Return on the money invested
ROCE
18.0%
Strong — 18.0% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+5.9%
Slow sales growth (+5.9% YoY)
Profit growth
EPS YoY
+31.5%
Earnings growing fast (+31.5% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
6/8 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
137%
Turns 137% of profit into real cash
Spare cash per sale
FCF Margin
23.3%
Converts sales into free cash efficiently (23.3%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.65
Moderate — manageable debt (0.65)
Covers its interest
Interest Cover
20.32x
Comfortably covers interest (20.3x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
33.6x
Pricey — P/E 33.6

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year
P/E vs Forward
-4.4
SLOWING
Earnings expected to fall — forward P/E higher than today

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial